Internal Medicine, Rheumatology · Tulsa, OK
NPI
1396744678
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
6160 S Yale Ave
Tulsa, OK, 74136
Phone (918) 497-3140
Groups this clinician bills Medicare through
Medicare paid, 2024
$103K
4,390 services
Medicare patients, 2024
867
Average age 71
Drug cost, 2024
$5.1M
13,340 prescriptions
Company payments, 2025
$2,430
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manuel J Calvin was code J1010 (injection, methylprednisolone acetate, 1 mg), 2,161 times for 27 patients. In total Manuel J Calvin billed 4,390 services in 25 codes, and Medicare paid $103K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,161 | 27 | $0.10 | $213 |
| 99214 Office E&M - Established | Office | 1,071 | 839 | $80.90 | $87K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 789 | 650 | $11.08 | $8,745 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 174 | 32 | $0.70 | $122 |
| 96372 Injection Administration | Office | 40 | 36 | $9.27 | $371 |
| 20610 Joint Injection | Office | 21 | 18 | $46.44 | $975 |
| 99213 Office E&M - Established | Office | 20 | 19 | $48.79 | $976 |
| 99222 Hospital E&M - Initial | Facility | 11 | 11 | $97.25 | $1,070 |
By year: 2022 $110K for 1,683 services; 2023 $96K for 1,441 services; 2024 $103K for 4,390 services.
Medicare prescription drug claims, 2024
In 2024, the drug Manuel J Calvin prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,669 prescriptions and refills. In total Manuel J Calvin wrote 13,340 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,669 | 3,368 | 436 | $82K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,136 | 1,137 | 190 | $40K |
| Prednisone Generic | 757 | 1,194 | 242 | $4,600 |
| Methotrexate Methotrexate Sodium | 697 | 1,289 | 188 | $17K |
| Gabapentin Generic | 438 | 690 | 93 | $7,717 |
| Tramadol Hcl Generic | 406 | 437 | 84 | $3,753 |
| Tizanidine Hcl Generic | 393 | 584 | 91 | $5,882 |
| Sulfasalazine Dr Sulfasalazine | 386 | 648 | 104 | $13K |
| Oxycodone Hcl Generic | 386 | 386 | 53 | $5,952 |
| Leflunomide Generic | 334 | 595 | 91 | $29K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 324 | 324 | 53 | $11K |
| Cyclobenzaprine Hcl Generic | 290 | 389 | 66 | $4,093 |
| Sulfasalazine Generic | 255 | 437 | 52 | $7,407 |
| Celecoxib Generic | 245 | 417 | 69 | $8,640 |
| Pregabalin Generic | 217 | 259 | 39 | $4,618 |
Brand drugs: - claims; generic drugs: 11,817 claims; opioid claims: 2,806.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manuel J Calvin $2,430 ($2,430 in general payments such as food, travel and fees) from 10 companies. The largest payer was Abbvie Inc. with $785.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 41 | $785 |
| Amgen Inc. AMGN | 47 | $633 |
| Pfizer Inc. PFE | 14 | $320 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $215 |
| UCB, Inc. UCB.BR | 7 | $151 |
| GlaxoSmithKline, LLC. GSK | 7 | $137 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $86.96 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $51.17 |
| Mallinckrodt Hospital Products Inc. | 1 | $35.04 |
| Genentech USA, Inc. ROG.SW | 1 | $14.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.